← Patent-cliff monitor small molecule SOTYKTU DEUCRAVACITINIB
Loss of exclusivity February 2043 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name SOTYKTU Active ingredient DEUCRAVACITINIB Strength 6MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2022 Marketing status RX
Listed patents Patent Expires Type 12521390 February 2043 product RE47929 November 2033 substance, product 11021475 November 2033 use U-3434 10000480 November 2033 substance, product
Regulatory exclusivity Code Expires I-986 March 2029 NCE September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.